Experimental cell therapy takes on stubborn autoimmune diseases
NCT ID NCT07049081
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals were to check safety and find the right dose, but the study was stopped early, so we have limited information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LUCAR-G79 T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases like lupus.
What could go wrong
This was a very early, tiny study (only 3 people) that was terminated, so results are limited. Cell therapies can have serious side effects, and it's unclear if this approach will work for autoimmune conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
-
The Third The People's Hospital of Bengbu
Bengbu, Anhui, China
-
The second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China